Evidence map›Paper›PMID 37294447›Full record

ArticleJournal of ophthalmic inflammation and infection2023

Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial.

Amit K Reddy, D Claire Miller, Amol A Sura, S R Rathinam, John A Gonzales, Radhika Thundikandy, Anuradha Kanakath, Bala Murugan, Rajesh Vedhanayaki, Lyndell L Lim and 6 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ophthalmic inflammation and infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01829295 (First-line Antimetabolites as Steroid-sparing Treatment), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01829295 phase3completednot on this map

First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial

TypeinterventionalSponsorUniversity of California, San FranciscoRan2013 to 2018Enrolled216ConditionsUveitisArmsMycophenolate mofetil, Methotrexate, Prednisone
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 5 countries.

Amit K ReddyF.I. Proctor Foundation, University of California, San Francisco, 490 Illinois St Fl 2, San Francisco, CA, 94158, USA.
D Claire MillerF.I. Proctor Foundation, University of California, San Francisco, 490 Illinois St Fl 2, San Francisco, CA, 94158, USA.
Amol A SuraF.I. Proctor Foundation, University of California, San Francisco, 490 Illinois St Fl 2, San Francisco, CA, 94158, USA.
S R RathinamAravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Uvea Services, Madurai, India.
John A GonzalesF.I. Proctor Foundation, University of California, San Francisco, 490 Illinois St Fl 2, San Francisco, CA, 94158, USA.
Radhika ThundikandyAravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Uvea Services, Madurai, India.
Anuradha KanakathAravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Uvea Services, Coimbatore, India.
Bala MuruganAravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Uvea Services, Pondicherry, India.
Rajesh VedhanayakiAravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Uvea Services, Madurai, India.
Lyndell L LimCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
Eric B SuhlerCasey Eye Institute, Oregon Health and Science University, Potland, OR, USA.
Thuy DoanF.I. Proctor Foundation, University of California, San Francisco, 490 Illinois St Fl 2, San Francisco, CA, 94158, USA.
Hassan A Al-DhibiDivision of Vitreoretinal Surgery and Uveitis, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia.
Debra A GoldsteinDepartment of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Lourdes Arellanes-GarciaAsociación Para Evitar la Ceguera, Mexico City, Mexico.
Nisha R AcharyaF.I. Proctor Foundation, University of California, San Francisco, 490 Illinois St Fl 2, San Francisco, CA, 94158, USA. nisha.acharya@ucsf.edu.
University of California, San Francisco · USAravind Eye Hospital · INAsociacion Para Evitar la Ceguera en México Hospital Dr. Luis Sánchez Bulnes · MXCentre for Eye Research Australia · AUKing Khaled Eye Specialist Hospital · SANorthwestern University · USOregon Health & Science University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe antimetabolites methotrexate (MTX) and mycophenolate mofetil (MMF) are commonly used as initial corticosteroid-sparing treatment for uveitis. There is little data examining risk factors for failing both MTX and MMF. The objective of this study is to determine risk factors for failing both MTX and MMF in patients with non-infectious uveitis. MAIN BODY: This is a sub-analysis of the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial, which was an international, multicenter, block-randomized, observer-masked, comparative effectiveness trial comparing MTX and MMF as initial treatments for non-infectious uveitis. This study was undertaken at multiple referral centers in India, the United States, Australia, Saudi Arabia and Mexico between 2013 and 2017. A total of 137 patients who completed all 12 months of follow-up from the FAST trial, were included in this study. The primary outcome was failing both antimetabolites over the 12 months of the trial. Potential predictors included: age, sex, bilateral involvement, anatomic location of the uveitis, presence of cystoid macular edema (CME) and retinal vasculitis at baseline visit, uveitis duration, and country/study sites as risk factors for failing both MTX and MMF. The presence of retinal vasculitis posterior to the equator on fluorescein angiogram was associated with failing both MTX and MMF.

conclusionRetinal vasculitis may be a risk factor for failing multiple antimetabolites. Clinicians could consider more quickly advancing these patients to other medication classes, such as biologics.

Indexed as

Immunomodulatory therapyMethotrexateMycophenolate mofetilNon-infectious uveitisRetinal vasculitis

Identifiers

PMID37294447
PMCPMC10256664
OpenAlexW4379967046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.